Parameter
| Biomarker | piR-823 (PIWI interacting RNA-823) | Full name | PIWI-interacting RNA-823 | Molecular Type | Non-coding RNA (piRNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis and Prognosis | ||
| Disease | Gastric Cancer | Disease Subtypes | / | ||
| Organ | Stomach | Test Sample / Technology Platform | Serum (qPCR, digital PCR), tumor tissue (qPCR) | ||
| Pathobiological Mechanisms | piRNA, the low expression of piR-823 in gastric cancer tissues and serum, inhibits tumor cell proliferation by regulating DNA methylation (such as inhibiting c-MYC promoter methylation), and low expression is positively correlated with tumor stage and distant metastasis | ||||
| Clinical Availability Status | Basic research: in the stage of cell experiments and small clinical samples, the mechanism and clinical value need to be further verified | ||||
| Notes and Dynamics | piRNA has been rarely studied in gastric cancer, but its high stability (especially in serum) makes it have potential diagnostic advantages. The combined detection of PIRNA and piR-823 can improve the diagnostic accuracy, which is a new direction for the research of non-coding RNA markers in gastric cancer | ||||